知镜 Cognispect · 医学文献与研究工作台

Patient-derived organoids in hematologic malignancies: Fidelity and translation beyond animals.

Nie L, Jiang V, Liu Y, Wang M.
Trends in cancer · 2026-06-27 · PMID 42362433

文献摘要

Hematologic patient-derived organoids (PDOs) reconstruct human bone marrow and lymph node microenvironments in 3D, preserving malignant cell states, clonal diversity, and clinically relevant drug responses. Leukemia PDOs artificially mimic the complex bone marrow niche and cytokine dependencies. Lymphoma PDOs recapture immune-stromal interactions and enable testing of targeted and immunotherapies, including bispecific antibodies and chimeric antigen receptor (CAR) T-cells. Multiple myeloma PDOs model the bone marrow microenvironment and maintain plasma tumor cell survival cues that drive drug resistance. Across preclinical models, PDOs outperform 2D cultures, spheroids, and xenografts in mechanistic and translational resolution. Converging regulatory support and National Institutes of Health investment position hematologic PDOs as frontline platforms for functional precision oncology. This review highlights current systems, disease-specific advances, quality standards, and future directions.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。